0 XP   0   0   0

Bliss GVS Pharma Limited
Buy, Hold or Sell?

Should you buy, hold or sell Bliss GVS Pharma Limited?

I guess you are interested in Bliss GVS Pharma Limited. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

Let's analyse Bliss GVS Pharma Limited

Let's start. I'm going to help you getting a better view of Bliss GVS Pharma Limited. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

  1. Company's Financial Health
    A deep dive into the books. How are the numbers doing? Is Bliss GVS Pharma Limited even making a profit? Is the company skyrocketing? Or is it sinking like the Titanic. The trend is your friend.
  2. Market Valuation
    Finally, you now have an insight of how Bliss GVS Pharma Limited is doing in the market. If the company is worth buying. The latest step is to find out how other investors value Bliss GVS Pharma Limited. The closing price on 2023-02-03 was INR73.65 per share. Is the company over- or underpriced?
  3. Key Performance Indicators
    A total overlook on how the company is doing. Based on the (trends in) the key performance indicators.
Bliss GVS Pharma Limited Daily Candlestick Chart
Bliss GVS Pharma Limited Daily Candlestick Chart
Summary









1. Valuation of Bliss GVS Pharma Limited




Current price per share

INR73.65

2. Growth of Bliss GVS Pharma Limited




Is Bliss GVS Pharma Limited growing?

Current yearPrevious yearGrowGrow %
How rich?$99.8m$98.6m$1.2m1.3%

How much money is Bliss GVS Pharma Limited making?

Current yearPrevious yearGrowGrow %
Making money$1.8m$8.3m-$6.5m-355.4%
Net Profit Margin2.0%11.9%--

How much money comes from the company's main activities?

3. Financial Health of Bliss GVS Pharma Limited




Comparing to competitors in the Drug Manufacturers - Major industry




  Industry Rankings (Drug Manufacturers - Major)  


Richest
#7 / 12

Most Profit
#12 / 12


Summary

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a profit.
Using its assets, the company is less efficient in making profit.
Using its investors money, the company is inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is very efficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

1.1. Profitability of Bliss GVS Pharma Limited.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Bliss GVS Pharma Limited earns for each ₹1 of revenue.

  • Above 10% is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Net Profit Margin of 2.0% means that ₹0.02 for each ₹1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Bliss GVS Pharma Limited:

  • The MRQ is 2.0%. The company is making a profit. +1
  • The TTM is 2.0%. The company is making a profit. +1
Trends
Current periodCompared to+/- 
MRQ2.0%TTM2.0%0.0%
TTM2.0%YOY11.9%-9.9%
TTM2.0%5Y11.5%-9.5%
5Y11.5%10Y13.3%-1.8%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ2.0%10.8%-8.8%
TTM2.0%10.8%-8.8%
YOY11.9%14.8%-2.9%
5Y11.5%12.2%-0.7%
10Y13.3%11.9%+1.4%
1.1.2. Return on Assets

Shows how efficient Bliss GVS Pharma Limited is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • 1.4% Return on Assets means that Bliss GVS Pharma Limited generated ₹0.01 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Bliss GVS Pharma Limited:

  • The MRQ is 1.4%. Using its assets, the company is less efficient in making profit.
  • The TTM is 1.4%. Using its assets, the company is less efficient in making profit.
Trends
Current periodCompared to+/- 
MRQ1.4%TTM1.4%0.0%
TTM1.4%YOY6.4%-5.0%
TTM1.4%5Y7.5%-6.2%
5Y7.5%10Y8.1%-0.5%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.4%1.8%-0.4%
TTM1.4%2.3%-0.9%
YOY6.4%3.0%+3.4%
5Y7.5%3.0%+4.5%
10Y8.1%2.7%+5.4%
1.1.3. Return on Equity

Shows how efficient Bliss GVS Pharma Limited is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • 1.8% Return on Equity means Bliss GVS Pharma Limited generated ₹0.02 for each ₹1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Bliss GVS Pharma Limited:

  • The MRQ is 1.8%. Using its investors money, the company is inefficient in making profit. -1
  • The TTM is 1.8%. Using its investors money, the company is inefficient in making profit. -1
Trends
Current periodCompared to+/- 
MRQ1.8%TTM1.8%0.0%
TTM1.8%YOY8.5%-6.6%
TTM1.8%5Y10.7%-8.9%
5Y10.7%10Y13.6%-2.9%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ1.8%2.5%-0.7%
TTM1.8%3.9%-2.1%
YOY8.5%4.4%+4.1%
5Y10.7%4.2%+6.5%
10Y13.6%4.0%+9.6%

1.2. Operating Efficiency of Bliss GVS Pharma Limited.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Bliss GVS Pharma Limited is operating .

  • Measures how much profit Bliss GVS Pharma Limited makes for each ₹1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • An Operating Margin of 0.0% means the company generated ₹0.00  for each ₹1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Bliss GVS Pharma Limited:

  • The MRQ is 0.0%. The data is not here.
Trends
Current periodCompared to+/- 
MRQ-TTM-0.0%
TTM-YOY-0.0%
TTM-5Y13.6%-13.6%
5Y13.6%10Y19.7%-6.1%
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ-29.7%-29.7%
TTM-11.5%-11.5%
YOY-11.7%-11.7%
5Y13.6%12.0%+1.6%
10Y19.7%11.0%+8.7%
1.2.2. Operating Ratio

Measures how efficient Bliss GVS Pharma Limited is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • An Operation Ratio of 0.53 means that the operating costs are ₹0.53 for each ₹1 in net sales.

Let's take a look of the Operating Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 0.534. The company is very efficient in keeping operating costs low. +2
  • The TTM is 0.534. The company is very efficient in keeping operating costs low. +2
Trends
Current periodCompared to+/- 
MRQ0.534TTM0.5340.000
TTM0.534YOY0.584-0.050
TTM0.5345Y1.099-0.565
5Y1.09910Y1.272-0.173
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.5340.475+0.059
TTM0.5340.425+0.109
YOY0.5840.731-0.147
5Y1.0990.943+0.156
10Y1.2720.983+0.289

1.3. Liquidity of Bliss GVS Pharma Limited.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Bliss GVS Pharma Limited is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A Current Ratio of 3.33 means the company has ₹3.33 in assets for each ₹1 in short-term debts.

Let's take a look of the Current Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 3.329. The company is very able to pay all its short-term debts. +2
  • The TTM is 3.329. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ3.329TTM3.3290.000
TTM3.329YOY3.758-0.428
TTM3.3295Y3.213+0.117
5Y3.21310Y2.521+0.691
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ3.3291.824+1.505
TTM3.3291.800+1.529
YOY3.7581.807+1.951
5Y3.2131.305+1.908
10Y2.5211.218+1.303
1.3.2. Quick Ratio

Measures if Bliss GVS Pharma Limited is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Quick Ratio of 2.84 means the company can pay off ₹2.84 for each ₹1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 2.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 2.843. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ2.843TTM2.8430.000
TTM2.843YOY2.980-0.137
TTM2.8435Y2.626+0.216
5Y2.62610Y1.955+0.671
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ2.8431.248+1.595
TTM2.8431.200+1.643
YOY2.9801.151+1.829
5Y2.6260.836+1.790
10Y1.9550.750+1.205

1.4. Solvency of Bliss GVS Pharma Limited.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Bliss GVS Pharma Limited assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Bliss GVS Pharma Limited to Drug Manufacturers - Major industry mean.
  • A Debt to Asset Ratio of 0.26 means that Bliss GVS Pharma Limited assets are financed with 26.2% credit (debt) and the remaining percentage (100% - 26.2%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 0.262. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.262. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.262TTM0.2620.000
TTM0.262YOY0.249+0.012
TTM0.2625Y0.292-0.030
5Y0.29210Y0.378-0.086
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.2620.415-0.153
TTM0.2620.419-0.157
YOY0.2490.429-0.180
5Y0.2920.455-0.163
10Y0.3780.431-0.053
1.4.2. Debt to Equity Ratio

Measures if Bliss GVS Pharma Limited is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A Debt to Equity ratio of 35.4% means that company has ₹0.35 debt for each ₹1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 0.354. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.354. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.354TTM0.3540.000
TTM0.354YOY0.332+0.022
TTM0.3545Y0.418-0.064
5Y0.41810Y0.662-0.244
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ0.3540.675-0.321
TTM0.3540.698-0.344
YOY0.3320.738-0.406
5Y0.4180.840-0.422
10Y0.6620.814-0.152

2. Market Valuation of Bliss GVS Pharma Limited

2. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every ₹1 in earnings Bliss GVS Pharma Limited generates.

  • Above 15 is considered overpriced but always compare Bliss GVS Pharma Limited to the Drug Manufacturers - Major industry mean.
  • A PE ratio of 53.04 means the investor is paying ₹53.04 for every ₹1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Bliss GVS Pharma Limited:

  • The EOD is 50.770. Good. +1
  • The MRQ is 53.045. Good. +1
  • The TTM is 53.045. Good. +1
Trends
Current periodCompared to+/- 
EOD50.770MRQ53.045-2.275
MRQ53.045TTM53.0450.000
TTM53.045YOY14.864+38.180
TTM53.0455Y25.576+27.469
5Y25.57610Y22.146+3.429
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD50.77073.229-22.459
MRQ53.04566.328-13.283
TTM53.04560.797-7.752
YOY14.86433.289-18.425
5Y25.57660.412-34.836
10Y22.14664.422-42.276
2.2. Price Earnings to Growth Ratio

Measures the predicted future growth of Bliss GVS Pharma Limited.

  • Lower is better.
  • A PEG ratio of 1 means the market price of the stock and the expected future earnings are on par.

Let's take a look of the Price Earnings to Growth Ratio trends of Bliss GVS Pharma Limited:

  • The MRQ is 242.801. Seems overpriced? -1
  • The TTM is 242.801. Seems overpriced? -1
Trends
Current periodCompared to+/- 
MRQ242.801TTM242.8010.000
TTM242.801YOY21.109+221.692
TTM242.8015Y66.495+176.306
5Y66.49510Y47.685+18.810
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
MRQ242.801-0.235+243.036
TTM242.8010.137+242.664
YOY21.1090.124+20.985
5Y66.4950.232+66.263
10Y47.6850.222+47.463

2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Bliss GVS Pharma Limited is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Drug Manufacturers - Major industry mean).
  • A PB ratio of 0.97 means the investor is paying ₹0.97 for each ₹1 in book value.

Let's take a look of the Price to Book Ratio trends of Bliss GVS Pharma Limited:

  • The EOD is 0.933. Very good. +2
  • The MRQ is 0.974. Very good. +2
  • The TTM is 0.974. Very good. +2
Trends
Current periodCompared to+/- 
EOD0.933MRQ0.974-0.042
MRQ0.974TTM0.9740.000
TTM0.974YOY1.260-0.285
TTM0.9745Y2.056-1.081
5Y2.05610Y2.501-0.446
Compared to industry (Drug Manufacturers - Major)
PeriodCompanyIndustry (mean)+/- 
EOD0.9331.495-0.562
MRQ0.9741.439-0.465
TTM0.9741.890-0.916
YOY1.2602.460-1.200
5Y2.0561.972+0.084
10Y2.5012.221+0.280
2. Total Gains per Share

3. Summary

3.1. Key Performance Indicators

The key performance indicators of Bliss GVS Pharma Limited compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share--0.6060.6060%7.042-91%6.358-90%8.774-93%
Book Value Growth--1.0131.0130%1.099-8%1.111-9%1.137-11%
Book Value Per Share--78.96678.9660%78.359+1%68.652+15%54.818+44%
Book Value Per Share Growth--1.0081.0080%1.099-8%1.110-9%1.136-11%
Current Ratio--3.3293.3290%3.758-11%3.213+4%2.521+32%
Debt To Asset Ratio--0.2620.2620%0.249+5%0.292-10%0.378-31%
Debt To Equity Ratio--0.3540.3540%0.332+7%0.418-15%0.662-46%
Dividend Per Share--0.5140.5140%0.538-5%0.757-32%0.699-27%
Dividend Per Share Growth--0.9550.9550%0.444+115%1.042-8%1.087-12%
Eps--1.4511.4510%6.640-78%7.043-79%6.772-79%
Eps Growth--0.2180.2180%0.704-69%0.906-76%1.045-79%
Free Cash Flow Per Share--5.9305.9300%5.317+12%1.680+253%3.890+52%
Free Cash Flow Per Share Growth--1.1151.1150%5.661-80%1.287-13%3.672-70%
Free Cash Flow To Equity Per Share--3.6413.6410%3.301+10%-0.402+111%1.648+121%
Free Cash Flow To Equity Per Share Growth--1.1031.1030%3.810-71%1.025+8%1.528-28%
Gross Profit Margin--1.0001.0000%1.0000%1.0000%1.0000%
Intrinsic Value_10Y_max--246.806--------
Intrinsic Value_10Y_min--205.398--------
Intrinsic Value_1Y_max--10.006--------
Intrinsic Value_1Y_min--9.723--------
Intrinsic Value_3Y_max--41.286--------
Intrinsic Value_3Y_min--38.791--------
Intrinsic Value_5Y_max--86.097--------
Intrinsic Value_5Y_min--78.135--------
Net Profit Margin--0.0200.0200%0.119-83%0.115-83%0.133-85%
Operating Margin----0%-0%0.136-100%0.197-100%
Operating Ratio--0.5340.5340%0.584-9%1.099-51%1.272-58%
Pb Ratio0.933-4%0.9740.9740%1.260-23%2.056-53%2.501-61%
Pe Ratio50.770-4%53.04553.0450%14.864+257%25.576+107%22.146+140%
Peg Ratio--242.801242.8010%21.109+1050%66.495+265%47.685+409%
Price Per Share73.650-4%76.95076.9500%98.700-22%130.350-41%125.383-39%
Price To Total Gains Ratio65.745-4%68.69068.6900%13.020+428%28.586+140%23.073+198%
Profit Growth--0.2200.2200%0.704-69%0.906-76%1.046-79%
Quick Ratio--2.8432.8430%2.980-5%2.626+8%1.955+45%
Return On Assets--0.0140.0140%0.064-79%0.075-82%0.081-83%
Return On Equity--0.0180.0180%0.085-78%0.107-83%0.136-87%
Revenue Growth--1.2951.2950%0.837+55%1.245+4%1.187+9%
Total Gains Per Share--1.1201.1200%7.580-85%7.115-84%9.473-88%
Total Gains Per Share Growth--0.1480.1480%0.766-81%0.911-84%0.878-83%
Usd Book Value--99881607.40099881607.4000%98606927.000+1%86493268.840+15%69039360.800+45%
Usd Book Value Change Per Share--0.0070.0070%0.086-91%0.078-90%0.107-93%
Usd Book Value Per Share--0.9630.9630%0.956+1%0.838+15%0.669+44%
Usd Dividend Per Share--0.0060.0060%0.007-5%0.009-32%0.009-27%
Usd Eps--0.0180.0180%0.081-78%0.086-79%0.083-79%
Usd Free Cash Flow----0%-0%-0%-0%
Usd Free Cash Flow Per Share--0.0720.0720%0.065+12%0.020+253%0.047+52%
Usd Free Cash Flow To Equity Per Share--0.0440.0440%0.040+10%-0.005+111%0.020+121%
Usd Price Per Share0.899-4%0.9390.9390%1.204-22%1.590-41%1.530-39%
Usd Profit--1834904.4001834904.4000%8355889.800-78%8864595.640-79%8522840.022-78%
Usd Revenue--91189400.20091189400.2000%70419058.800+29%80147490.080+14%67651281.400+35%
Usd Total Gains Per Share--0.0140.0140%0.092-85%0.087-84%0.116-88%
 EOD+3 -2MRQTTM+0 -0YOY+14 -265Y+18 -2310Y+17 -24

3.2. Fundamental Score

Let's check the fundamental score of Bliss GVS Pharma Limited based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-1550.770
Price to Book Ratio (EOD)Between0-10.933
Net Profit Margin (MRQ)Greater than00.020
Operating Margin (MRQ)Greater than00.000
Quick Ratio (MRQ)Greater than12.843
Current Ratio (MRQ)Greater than13.329
Debt to Asset Ratio (MRQ)Less than10.262
Debt to Equity Ratio (MRQ)Less than10.354
Return on Equity (MRQ)Greater than0.150.018
Return on Assets (MRQ)Greater than0.050.014
Total6/10 (60.0%)

3.3. Technical Score

Let's check the technical score of Bliss GVS Pharma Limited based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5049.161
Ma 20Greater thanMa 5073.503
Ma 50Greater thanMa 10073.056
Ma 100Greater thanMa 20074.557
OpenGreater thanClose74.600
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2022-03-31. Currency in INR. All numbers in thousands.

Summary
Total Assets11,087,466
Total Liabilities2,900,449
Total Stockholder Equity8,187,017
 As reported
Total Liabilities 2,900,449
Total Stockholder Equity+ 8,187,017
Total Assets = 11,087,466

Assets

Total Assets11,087,466
Total Current Assets7,760,341
Long-term Assets7,760,341
Total Current Assets
Cash And Cash Equivalents 135,556
Short-term Investments 1,239,557
Net Receivables 3,927,500
Inventory 1,774,500
Other Current Assets 425,849
Total Current Assets  (as reported)7,760,341
Total Current Assets  (calculated)7,502,962
+/- 257,379
Long-term Assets
Property Plant Equipment 2,948,237
Goodwill 77,111
Intangible Assets 3,828
Long-term Assets  (as reported)0
Long-term Assets  (calculated)3,029,176
+/- 3,029,176

Liabilities & Shareholders' Equity

Total Current Liabilities2,330,862
Long-term Liabilities-
Total Stockholder Equity8,187,017
Total Current Liabilities
Short-term Debt 817,350
Total Current Liabilities  (as reported)2,330,862
Total Current Liabilities  (calculated)817,350
+/- 1,513,512
Long-term Liabilities
Long term Debt Total 267,141
Long-term Liabilities  (as reported)0
Long-term Liabilities  (calculated)267,141
+/- 267,141
Total Stockholder Equity
Common Stock103,678
Retained Earnings 8,040,684
Capital Surplus 212,768
Other Stockholders Equity -170,113
Total Stockholder Equity (as reported)8,187,017
Total Stockholder Equity (calculated)8,187,017
+/-0
Other
Cash And Equivalents83,596
Cash and Short Term Investments 1,458,709
Common Stock Shares Outstanding 103,678
Liabilities and Stockholders Equity 11,087,466



Balance Sheet

Currency in INR. All numbers in thousands.

 Trend2022-03-312021-03-312020-03-312019-03-312018-03-312017-03-312016-03-312015-03-312014-03-31
> Total Assets 
5,827,856
6,621,682
7,617,818
10,229,050
8,600,341
9,048,770
10,290,236
10,767,858
11,087,466
11,087,46610,767,85810,290,2369,048,7708,600,34110,229,0507,617,8186,621,6825,827,856
   > Total Current Assets 
3,516,962
4,170,776
4,705,482
5,659,321
6,874,266
6,936,150
7,729,493
7,651,996
7,760,341
7,760,3417,651,9967,729,4936,936,1506,874,2665,659,3214,705,4824,170,7763,516,962
       Cash And Cash Equivalents 
803,721
572,893
130,531
435,086
181,500
5,000
56,200
102,382
135,556
135,556102,38256,2005,000181,500435,086130,531572,893803,721
       Short-term Investments 
0
0
0
503,115
115,529
718,241
248,797
651,490
1,239,557
1,239,557651,490248,797718,241115,529503,115000
       Net Receivables 
2,248,029
2,639,879
3,009,329
2,544,538
2,984,839
4,607,299
5,479,118
4,638,203
3,927,500
3,927,5004,638,2035,479,1184,607,2992,984,8392,544,5383,009,3292,639,8792,248,029
       Inventory 
325,304
337,000
680,057
492,987
590,335
773,674
932,861
1,190,461
1,774,500
1,774,5001,190,461932,861773,674590,335492,987680,057337,000325,304
       Other Current Assets 
137,211
616,812
416,185
1,516,259
1,763,474
487,415
741,125
969,381
425,849
425,849969,381741,125487,4151,763,4741,516,259416,185616,812137,211
   > Long-term Assets 
0
0
0
4,503,913
1,726,075
2,112,620
2,560,743
0
0
002,560,7432,112,6201,726,0754,503,913000
       Property Plant Equipment 
1,431,824
1,598,263
1,900,162
2,588,340
1,267,794
1,815,375
2,326,162
2,278,234
2,948,237
2,948,2372,278,2342,326,1621,815,3751,267,7942,588,3401,900,1621,598,2631,431,824
       Goodwill 
736,964
737,600
437,564
424,308
96,477
96,477
77,111
77,111
77,111
77,11177,11177,11196,47796,477424,308437,564737,600736,964
       Long Term Investments 
101
101
1,102
1,002
0
0
0
0
0
000001,0021,102101101
       Intangible Assets 
7,612
7,937
5,760
66,263
5,178
5,268
6,423
5,785
3,828
3,8285,7856,4235,2685,17866,2635,7607,9377,612
> Total Liabilities 
2,857,418
3,101,934
3,491,594
5,362,845
3,237,948
2,588,784
2,934,106
2,685,323
2,900,449
2,900,4492,685,3232,934,1062,588,7843,237,9485,362,8453,491,5943,101,9342,857,418
   > Total Current Liabilities 
1,900,923
2,426,774
2,665,181
4,370,936
2,993,960
2,070,252
2,321,844
2,036,358
2,330,862
2,330,8622,036,3582,321,8442,070,2522,993,9604,370,9362,665,1812,426,7741,900,923
       Short-term Debt 
1,725,678
1,595,474
621,238
1,874,712
1,056,560
642,956
663,852
650,377
817,350
817,350650,377663,852642,9561,056,5601,874,712621,2381,595,4741,725,678
       Short Long Term Debt 
1,725,678
1,595,474
1,315,094
1,993,207
1,120,385
694,021
837,247
0
0
00837,247694,0211,120,3851,993,2071,315,0941,595,4741,725,678
       Accounts payable 
823,544
803,339
1,084,857
944,687
584,334
788,842
941,536
0
0
00941,536788,842584,334944,6871,084,857803,339823,544
       Other Current Liabilities 
216,028
585,786
620,005
1,262,644
1,269,199
557,007
491,724
0
0
00491,724557,0071,269,1991,262,644620,005585,786216,028
   > Long-term Liabilities 
0
0
0
565,694
129,207
379,889
464,671
0
0
00464,671379,889129,207565,694000
       Long term Debt Total 
0
0
382,427
255,804
59,155
325,375
403,586
344,330
267,141
267,141344,330403,586325,37559,155255,804382,42700
       Capital Lease Obligations 
0
0
0
0
0
0
51,633
0
0
0051,633000000
       Long-term Liabilities Other 
0
0
0
0
0
1,278
0
0
0
0001,27800000
       Deferred Long Term Liability 
14,236
4,326
0
0
0
0
0
0
0
00000004,32614,236
> Total Stockholder Equity
2,868,812
3,370,830
4,126,224
4,866,205
5,362,393
6,459,986
7,356,130
8,082,535
8,187,017
8,187,0178,082,5357,356,1306,459,9865,362,3934,866,2054,126,2243,370,8302,868,812
   Common Stock
103,147
103,147
103,147
103,147
103,147
103,147
103,147
103,147
103,678
103,678103,147103,147103,147103,147103,147103,147103,147103,147
   Retained Earnings 
2,692,718
3,200,037
3,961,949
4,709,711
5,220,557
6,333,146
7,187,863
7,924,814
8,040,684
8,040,6847,924,8147,187,8636,333,1465,220,5574,709,7113,961,9493,200,0372,692,718
   Accumulated Other Comprehensive Income 000000000
   Capital Surplus 
0
0
147,573
147,573
147,573
147,573
147,573
147,573
212,768
212,768147,573147,573147,573147,573147,573147,57300
   Treasury Stock000000000



Balance Sheet

Currency in INR. All numbers in thousands.




Cash Flow

Currency in INR. All numbers in thousands.




Income Statement

Currency in INR. All numbers in thousands.


Latest Income Statement (annual, 2022-03-31)

Gross Profit (+$)
totalRevenue7,474,541
Cost of Revenue-3,992,299
Gross Profit3,482,2423,482,242
 
Operating Income (+$)
Gross Profit3,482,242
Operating Expense--
Operating Income274,1553,482,242
 
Operating Expense (+$)
Research Development-
Selling General Administrative1,749,561
Selling And Marketing Expenses-
Operating Expense-1,749,561
 
Net Interest Income (+$)
Interest Income263,330
Interest Expense-16
Net Interest Income-263,314
 
Pretax Income (+$)
Operating Income274,155
Net Interest Income-
Other Non-Operating Income Expenses-
Income Before Tax (EBT)541,653274,155
EBIT - interestExpense = -16
150,402
150,418
Interest Expense16
Earnings Before Interest and Taxes (ebit)-541,669
Earnings Before Interest and Taxes (ebitda)-
 
After tax Income (+$)
Income Before Tax541,653
Tax Provision-310,388
Net Income From Continuing Ops-231,265
Net Income150,402
Net Income Applicable To Common Shares150,402
 
Non-recurring Events
Discontinued Operations-
Extraordinary Items-
Effect of Accounting Charges-
Other Items-
Non Recurring-
Other Operating Expenses-
Total Other Income/Expenses Net-0
 

Comments

Join the conversation.

Leave a comment

Stay informed with my latest content.

Subscribe to my newsletter and receive an email as soon as I add content to PenkeTrading.com.


By clicking Register, you agree to the General Terms and Conditions.
Penke's Market Notifications
ENLT.TA
1 hour ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of ENLT.TA.

ENLT.TA Daily Candlestick Chart
GBPEUR.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPEUR.FOREX.

GBPEUR.FOREX Daily Candlestick Chart
NZDPHP.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NZDPHP.FOREX.

NZDPHP.FOREX Daily Candlestick Chart
NZDIDR.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of NZDIDR.FOREX.

NZDIDR.FOREX Daily Candlestick Chart
MYRGBP.FOREX
4 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of MYRGBP.FOREX.

MYRGBP.FOREX Daily Candlestick Chart
GBPMYR.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPMYR.FOREX.

GBPMYR.FOREX Daily Candlestick Chart
GBPIDR.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPIDR.FOREX.

GBPIDR.FOREX Daily Candlestick Chart
SGDGBP.FOREX
4 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of SGDGBP.FOREX.

SGDGBP.FOREX Daily Candlestick Chart
GBPSGD.FOREX
4 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of GBPSGD.FOREX.

GBPSGD.FOREX Daily Candlestick Chart
CADNOK.FOREX
4 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of CADNOK.FOREX.

CADNOK.FOREX Daily Candlestick Chart
SVRT.TA
5 hours ago

I found you a Oversold RSI (Relative Strength Index) on the daily chart of SVRT.TA.

SVRT.TA Daily Candlestick Chart
PHTM.TA
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of PHTM.TA.

PHTM.TA Daily Candlestick Chart
NICE.TA
5 hours ago

I found you a Golden Cross on the daily chart of NICE.TA.

NICE.TA Daily Candlestick Chart
NFTA.TA
5 hours ago

I found you a MACD Bearish Hidden Divergence on the daily chart of NFTA.TA.

NFTA.TA Daily Candlestick Chart
ICB.TA
5 hours ago

I found you a STOCH Bullish Hidden Divergence on the daily chart of ICB.TA.

ICB.TA Daily Candlestick Chart
FRSX.TA
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of FRSX.TA.

FRSX.TA Daily Candlestick Chart
DCMA.TA
5 hours ago

I found you a Overbought RSI (Relative Strength Index) on the daily chart of DCMA.TA.

DCMA.TA Daily Candlestick Chart
ARD.TA
5 hours ago

I found you a Death Cross on the daily chart of ARD.TA.

ARD.TA Daily Candlestick Chart
MCRNT.TA
7 hours ago

I found you a STOCH Bearish Reversal Divergence on the daily chart of MCRNT.TA.

MCRNT.TA Daily Candlestick Chart